A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)

Type of Cancer
Genito-Urinary

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-374

To Learn More Call
201-510-0910

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Sponsor
AstraZeneca

Protocol Number
Astrazeneca D5082C00003

To Learn More Call
201-510-0910

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Sponsor
Genetech

Protocol Number
CO39303

To Learn More Call
201-510-0910

Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-920

To Learn More Call
201-510-0910

A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17712

To Learn More Call
201-510-0910

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Bayer

Protocol Number
Bayer 17777

To Learn More Call
201-510-0910

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Sponsor
Astellas

Protocol Number
9785-CL-0123

To Learn More Call
201-510-0910

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma